News
OBI Pharma has received clearance from the US FDA for an IND application for OBI-902 to begin a Phase I/II trial for advanced ...
Chengdu Origen and Vanotech have initiated the first subject dosing in the Phase I trial, VAN-2401, of KH658 for treating wet ...
AstraZeneca plans to submit the positive data Breztri Aerosphere in asthma for to regulatory authorities for review.
Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...
Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...
Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.
Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.
The US FDA has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III ACTION3 trial of DMX-200 for ...
Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...
The World Health Organization estimates that 50% of vaccines are wasted globally each year due to cold chain issues.
The FDA approved AstraZeneca's Truqap in November 2023 for the treatment of advanced HR-positive breast cancer.
The Imfinzi regimen reduced risk of death by 25%, with overall survival at two years at 82% compared to 75% in the control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results